Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats

Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction

(2020) Jonathan W. Cunningham et al.   JACC-Heart Failure

Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR‐181a in a Rodent Chronic Myocardial Infarction Model

(2020) Evgeniya Vaskova et al.   Journal of the American Heart Association

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date

(2020) Sara Akbar et al.   Therapeutics and Clinical Risk Management

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction

(2020) Douglas L. Mann et al.   JACC-Heart Failure

Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis

(2020) Virginia S. Hahn et al.   JACC-Heart Failure

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction

(2020) Francesco Giallauria et al.   Journal of Clinical Medicine

Interleukin-35 pretreatment attenuates lipopolysaccharide-induced heart injury by inhibition of inflammation, apoptosis and fibrotic reactions

(2020) Huan Hu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis

(2020) Christina Cho et al.   ONCOGENE

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

(2019) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug therapies in chronic heart failure: a focus on reduced ejection fraction

(2018) Helena Bolam et al.   CLINICAL MEDICINE

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure

(2018) Rishi K. Trivedi et al.   Journal of the American Heart Association

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

(2017) Clyde W. Yancy et al.   JOURNAL OF CARDIAC FAILURE

Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction

(2016) Constantijn Franssen et al.   JACC-Heart Failure

LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone

(2015) Hiroaki Kusaka et al.   AMERICAN JOURNAL OF HYPERTENSION

Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan

(2015) Brian Claggett et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

(2013) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment

(2010) B. A. Borlaug et al.   EUROPEAN HEART JOURNAL

Characteristics and Outcomes of Hospitalized Patients With Heart Failure and Reduced vs Preserved Ejection Fraction

(2009) Miyuki Tsuchihashi-Makaya et al.   CIRCULATION JOURNAL

The Pathophysiology of Heart Failure With Normal Ejection Fraction

(2009) Yu Ting Tan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY